Exhibit 99.1

Entera Announces Second Quarter 2026 Financial Results and Business Updates

U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

Oversubscribed $275 Million Private Placement Led by BVF Partners L.P. (“BVF”) with Participation from Leading Institutional Healthcare Investors to Fund EB613 through Anticipated Submission of NDA to the FDA

EB613 Phase 3 Study Initiation Planned for Late 2026 with Topline Data Anticipated in the Second Half of 2028

IND Enabling Studies Ongoing for EB612 - the First Oral Peptide Replacement Tablet in Development for Patients with Hypoparathyroidism – Intention to File IND in First Half of 2027

TEL AVIV, August 7, 2026 -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today reported financial results and key business updates for the quarter ended June 30, 2026.

“The first half of 2026 marked one of the most consequential periods in Entera’s history. Since 2022, our core team embarked upon a journey of deconstruction and reconstruction to advance our science and optimize our pipeline. Despite scarce resources and particularly turbulent times, today, our N-Tab^® platform is developing one of the richest pipelines of clinical and near-clinical first in class oral peptide assets; and we have garnered the trust of global talent, luminaries, and financiers who support our mission and vision. Thank you. Osteoporosis is one of the foremost underserved health issues globally, and associated fracture rates continue to rise despite existing treatments. Our discussions with patients and their caregivers across primary care, gynecology, orthopedic surgery, rheumatology and endocrinology acknowledge the urgent need for new treatments, especially, an oral anabolic therapy. We are developing EB613 to address this treatment gap. Our plan is to do the same with EB612 for patients with hypoparathyroidism, also a women-centric condition. The capital raising transaction we announced on July 27, 2026, led by BVF is transformational for Entera. To our knowledge, the transaction is the largest biotech PIPE and the 9th largest PIPE, inclusive of the high-tech sector, on record in Israel. So, we shattered a few records and moving forward, we intend to continue to shatter more records across all our programs with a cohesive, global team of colleagues who are obsessed with our vision and steadfast in our execution,” said Miranda Toledano, Chief Executive Officer of Entera.

Key Recent Highlights

EB613: First Oral PTH(1-34) Anabolic Tablet for Osteoporosis

EB612: First-in-Class Oral Long-Acting PTH(1-34) Replacement Tablet for Hypoparathyroidism

EB618: First-in-Class Oral Dual GLP-1/Glucagon (Oxyntomodulin) Tablet for Obesity and Metabolic Disorders

Corporate Highlights

Financial Results for the Three Months Ended June 30, 2026

Cash and cash equivalents were $11.3 million as of June 30, 2026, and restricted cash was $7.1 million, primarily designated to fund the OPKO collaboration. On a pro forma basis, following the closing of the July 2026 private placement in which the Company received aggregate gross proceeds of approximately $275.0 million, the Company’s cash resources are expected to be sufficient to fully fund the planned Phase 3 registrational program of EB613 through topline results and the anticipated submission of an NDA to the FDA and to support the Company’s operations into 2030.

Research and development expenses for the three months ended June 30, 2026 were $3.2 million, as compared to $1.5 million for the three months ended June 30, 2025. The increase of $1.7 million was primarily attributable to increased materials, production and other costs related to the preparation of the EB613 Phase 3 program and to activities under the OPKO collaboration.

General and administrative expenses for the three months ended June 30, 2026 were $1.4 million, as compared to $1.1 million for the three months ended June 30, 2025.

Net loss was $7.3 million, or $0.14 per ordinary share (basic and diluted), for the three months ended June 30, 2026, as compared to $2.7 million, or $0.06 per ordinary share (basic and diluted), for the three months ended June 30, 2025. The increase was primarily driven by a $2.7 million non-cash fair value remeasurement of the pre-funded warrants issued in our April 2026 private placement, which are classified as a financial liability.

About Entera

Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages a disruptive and proprietary technology platform (N-Tab®) and its pipeline of first-in-class oral peptide programs. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet for osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n = 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is also developing the first oral Long-Acting PTH(1-34) tablet as a replacement therapy for patients with hypoparathyroidism (EB612), the first oral oxyntomodulin, a dual targeted GLP-1/glucagon peptide tablet for the treatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health, Inc. For more information on Entera, visit www.enterabio.com or follow us on LinkedIn, Twitter, and Facebook.

Cautionary Statement Regarding Forward Looking Statements

Various statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy, clinical development activities, collaboration arrangements and expected financial and operational results are forward-looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera’s forward-looking statements include, among others: the anticipated use of proceeds from the July 2026 private placement; the timing, design, and results of the planned Phase 3 registrational study of EB613; the FDA’s ongoing review of the EB613 program, including the terms and interpretation of the FDA’s feedback on our Clinical Amendment; the timing of the anticipated IND filings for EB612 and EB618 in collaboration with OPKO Health; the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s ability to establish and maintain development and commercialization collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statement Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10-K filed with the SEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

Company Contact:

IR@enterabio.com

ENTERA BIO LTD. 

CONDENSED CONSOLIDATED BALANCE SHEETS 

(U.S. dollars in thousands)

ENTERA BIO LTD. 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 

(U.S. dollars in thousands, except share and per share data) 

(Unaudited)